• L Pellegrini, E Milano, F Franceschi, G Belcaro, G Gizzi, B Feragalli, M Dugall, R Luzzi, S Togni, R Eggenhoffner, and L Giacomelli.
• Department SMO Biotech, Irvine3 Labs, Circulation Sciences, Chieti-Pescara University, Italy. Federico.franceschi@indena.com.
• Eur Rev Med Pharmacol Sci. 2016 Jun 1; 20 (12): 2695-700.

ObjectiveBoswellia serrata extracts (BSE) have been traditionally used for the treatment of several inflammatory diseases. The aim of this study was to evaluate the efficacy of a novel delivery form of BSE (Casperome®) in Ulcerative Colitis (UC) during minimally symptomatic remission phase.Patients And MethodsIn this open-label, observational, registry study, informed participants with UC in remission phase (n = 43) freely decided to receive the oral daily Casperome® supplementation (n = 22) or no supplementation (n = 21) for 4 weeks. Several parameters associated with minimally symptomatic UC in remission were evaluated at the inclusion and the end of the study.ResultsA significant beneficial effect of Casperome® was observed for all the parameters evaluated, namely: diffuse intestinal pain, evident and occult blood in stools, bowel movements and cramps, watery stools, malaise, anemia, rectal involvement, number of white blood cells as well as need for concomitant drugs and medical attention. Faecal concentration of calprotectin, a marker of bowel inflammation, resulted ameliorated in Casperome® supplemented patients.ConclusionsOur study showed that Casperome® supplementation attenuates symptoms associated with mild UC in remission, reducing the use of drugs and medical consultations. Therefore, our study suggests that Casperome® supplementation could represent a promising alternative approach to manage minimally symptomatic UC and maintain the remission phase.

10 keywords...

hide…